Adaptimmune Starts Planning TCR Commercialization For An Ultra Rare Patient Population

 
• By Alaric DeArment
  
Adaptimmune plans to file for approval of afami-cel in Q4 • Source: Shutterstock

More from Immuno-oncology

More from Anticancer